OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland. Show more
Location: 115 Pullman Crossing Road, Grasonville, MD, 21638, United States | Website: https://ostherapies.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
62.04M
52 Wk Range
$1.12 - $7.00
Previous Close
$1.85
Open
$1.88
Volume
259,207
Day Range
$1.79 - $1.88
Enterprise Value
79.58M
Cash
2.802M
Avg Qtr Burn
-2.89M
Insider Ownership
29.40%
Institutional Own.
1.84%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OST-HER2 Details Pediatric lung metastatic osteosarcoma | Phase 2b Data readout | |
OST-504 Details 2L prostate cancer | Phase 1b Data readout |